Welcome to the TCG Lifesciences blog, your gateway to understanding how we are transforming the landscape of drug discovery and development. As a premier global Contract Research and Contract Development and Manufacturing Organization (CRO & CDMO), TCG Lifesciences (TCGLS) is committed to delivering innovative solutions that cater to the diverse needs of pharmaceutical companies, biotechnology firms, and academic institutions across human health & animal health.
Exploring Our Comprehensive Service Offerings: Unparalleled Expertise in Drug Discovery and Development for last 20+ yrs
At TCGLS, we pride ourselves on providing a full spectrum of services that are critical to the success of drug discovery and development projects. Here’s an in-depth look at our core service offerings:
Medicinal Chemistry: Pioneering Innovative Solutions
Our medicinal chemistry team is at the forefront of designing and synthesizing novel chemical compounds. With a keen focus on optimizing properties conducive to drug development, we help our clients accelerate the discovery of new therapeutic agents. Our expertise ensures that each compound is crafted to meet the highest standards of efficacy and safety.
Biology Services: Bridging Science and Medicine
Our biology services encompass a wide array of offerings, including:
- Higher Throughput Screening (HTS): Identifying potential drug candidates quickly and efficiently.
- Assay Development: Creating robust and reliable assays for various biological targets.
- In Vitro and In Vivo Pharmacology Studies: Conducting comprehensive studies to understand the effects of compounds in biological systems.
- Target Validation: Ensuring that biological targets are suitable for drug development.
- Biomarker Discovery: Identifying and validating biomarkers that can guide drug development and patient stratification.
Chemical Biology: Decoding Complex Interactions
TCGLS leverages chemical biology to explore intricate biological systems and drug targets. By using chemical tools to investigate biochemical interactions, we gain valuable insights that drive the development of more effective and targeted therapies.
Computational Chemistry: Accelerating Drug Discovery
Our computational chemistry team employs advanced computational tools and algorithms to enhance the drug discovery process. Through Computer-Aided Drug Design (CADD) & Structure based drug design (SBDD), we streamline the identification and optimization of promising drug candidate molecules.
Analytical Services: Ensuring Precision and Accuracy
TCGLS offers a comprehensive suite of analytical chemistry services, including:
- Method Development and Validation: Developing and validating analytical methods to ensure reliable results.
- Impurity Identification: Detecting and identifying impurities to maintain the purity of drug candidates.
- Molecular Structure Elucidation: Determining the precise structure of compounds to support drug development efforts.
Preclinical Development: Building a Strong Foundation
Our preclinical development services provide the essential groundwork for evaluating potential drug candidates. We conduct In vitro ADME, pharmacokinetic (PK) studies and In vitro toxicology assessments to determine the safety and efficacy profiles of new compounds, ensuring they meet closer to regulatory requirements.
Bioinformatics: Integrating Data for Deeper Insights
TCGLS utilizes cutting-edge bioinformatics in a disease agnostic manner to analyze complex biological data, including genomics, transcriptomics, and proteomics. By integrating informatics and biology, we uncover unique MoA and nuances in biology that becomes crucial for an efficient discovery program.
Focusing on Therapeutic Areas
At TCGLS, we specialize in providing targeted solutions across a range of therapeutic areas, including:
- Inflammation and Pain Management: Developing therapies to alleviate pain and manage inflammatory conditions.
- Infectious Diseases: Innovating treatments to combat bacterial, viral, and other infectious agents.
- Central Nervous System Disorders: Creating novel therapies for neurological and psychiatric conditions.
- Oncology: Advancing cancer treatment through the discovery and development of new anti-cancer agents.
- Anti-infective: Strong success footprints in pre-clinical anti-bacterial discovery, seasoned campaigner in ant-candidal discovery and long precedence of working in preclinical anti-malarial discovery.
Partner with TCG Lifesciences
By partnering with TCG Lifesciences, you gain access to a wealth of expertise and state-of-the-art facilities. Our multidisciplinary teams work collaboratively to deliver high-quality, reliable, and timely results, helping you achieve your drug discovery and development goals.
Join us as we continue to push the boundaries of science and medicine, bringing hope and healing to patients worldwide. Stay connected for more updates on our latest research, achievements, and insights into the exciting field of drug discovery and development.
About Drug Discovery Innovation Programme 2024
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2024 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2024 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.